🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

ZTALMY

Marinus Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for rare genetic epilepsies and other seizure disorders, offering products like ZTALMY for cyclin-dependent kinase-like 5 deficiency disorder and developing ganaxolone for genetic epilepsy disorders.

Tags: ZTALMY, antiseizure medication, epilepsy treatments, genetic disorders, pharmaceutical

Symbol: MRNS

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. Scott N. Braunstein M.D.

Sector: Healthcare

Employees: 165

Address: 5 Radnor Corporate Center, Radnor, PA 19087

Phone: 484 801 4670

Leadership

  • Scott Braunstein, M.D., Chairman of the Board & Chief Executive Officer
  • Steven E. Pfanstiel, Chief Financial Officer and Chief Operating Officer
  • Joseph Hulihan, M.D., Chief Medical Officer
  • Christy Shafer, Chief Commercial Officer
  • Martha Manning, Esq., Senior Vice President, General Counsel and Secretary
  • Alex Aimetti, Ph.D., Chief Scientific Officer
  • Kimberly McCormick, PharmD, Chief Regulatory and Quality Assurance Officer
  • Sonya Weigle, SVP, Human Resources, IR & Corporate Affairs
  • David Czekai, Chief Chemistry, Manufacturing and Controls Officer
  • Tim M. Mayleben, Lead Independent Board Director
  • Chuck Austin, Director
  • Elan Ezickson, Director
  • Seth H.Z. Fischer, Director
  • Marvin H. Johnson, Jr., Director
  • Sara Nochur, Ph.D., Director
  • Christine Silverstein, Director
  • Sarah Noonberg, M.D., Ph.D., Director
  • ,
  • Josias, Clinical Trial Manager
  • Powell, Associate Director, Clinical Development Operations
  • Chasity, Regional Account Manager – Houston
  • Sandy, Regional Account Manager – Cincinnati
  • Amy, Regional Account Manager – Southeast
  • Tuula, Executive Director, Product Development

Last updated: 2024-12-31